-
Product Insights
New![]()
Net Present Value Model: Kyowa Kirin Co Ltd’s Rocatinlimab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Kyowa Kirin Co Ltd’s Bardoxolone Methyl
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
New![]()
Innovation and Patenting activity of Kirin Holdings Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Kirin Holdings Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
New![]()
Innovation and Patenting activity of Kyowa Kirin Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Kyowa Kirin Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Profile
![]()
Kirin Holdings Co Ltd – Company Profile
Kirin Holdings Co Ltd (Kirin) manufactures and markets alcoholic and non-alcoholic beverages and pharmaceuticals products. Its major products include beer, wine, hopposhu, new genre, sprits, chu-hi, whiskey, black tea, coffee, tea, fruit juice, dairy products, carbonated beverages, non-alcoholic beverages, flavored water, cosmetics and health foods, and pharmaceutical drugs. The company markets its products under Kirin Hyoketsu, Honkirin, James Squire, iMUSE, Cognizin, Kirin Gogo-no-Kocha, Kirin Nama-cha, XXXX, Kirin Ichiban, San Miguel Pale Pilsen, Four Roses, Spring Valley, Kirin FREE, Kirin Lemon...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: Ionis Pharmaceuticals Inc’s Evazarsen Sodium
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Sector Analysis
![]()
Taiwan Beer and Cider Market Overview by Category, Price Dynamics, Brand and Flavour, Distribution and Packaging, 2023
Taiwan Beer and Cider Market Overview The Taiwan beer and cider market size was LCU86.7 billion in 2022 and the market is expected to register a CAGR of less than 1% during 2023-2028. Taiwan Beer and Cider Market Outlook, 2022-2028 (LCU Billion) Buy the Full Report for More Insights into the Taiwan Beer and Cider Market Forecast Download a Free Report Sample The Taiwan beer and cider market research report provides detailed data analysis of the beer and cider sector...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rocatinlimab in Atopic Dermatitis (Atopic Eczema)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rocatinlimab in Atopic Dermatitis (Atopic Eczema) Drug Details: Rocatinlimab is under development for the treatment...
-
Product Insights
New![]()
X-Linked Hypophosphatemic Rickets Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
X-Linked Hypophosphatemic Rickets Clinical Trials Overview The X-Linked Hypophosphatemic Rickets clinical trial report consists of 55 trials. The report provides an overview of the X-Linked Hypophosphatemic Rickets clinical trial scenario. The report provides top-line data relating to the clinical trials on X-Linked Hypophosphatemic Rickets. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AT-1412 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AT-1412 in Solid Tumor Drug Details:KBA-1412 is under development for the treatment of solid tumors, melanoma....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.